Tehran University of Medical Sciences

Science Communicator Platform

Share By
Assessment of Immunogenicity of Multi-Epitope Dna Vaccine Encoding Cdpk3, Rop22 & Mic8 of Toxoplasma Gondii Adjuvanted With Il-12 Against Acute and Chronic Toxoplasmosis in Balb/C Mice



Abasi E ; Khademvatan S ; Shojaee S ; Mohebali M ; Foroutan M ; Zeraati H ; Valian HK
Authors

Source: Iranian Journal of Parasitology Published:2026

Abstract

Background: A non-allergenic, immunogenic recombinant DNA plasmid encoding CDPK3, MIC8, and ROP22 epitopes was evaluated as a DNA vaccine against Toxoplasma gondii in BALB/c mice, used in combination with IL-12 as a genetic adjuvant, to assess protection against both acute and chronic toxoplasmosis. Methods: BALB/c mice were immunized three times at two-week intervals with the DNA vaccine combined with IL-12. Humoral immune responses were measured by total IgG, IgG1, and IgG2a levels, while cellular responses were evaluated through interferon-γ production and lymphocyte proliferation assays. Protective efficacy was assessed using challenge models with T. gondii: the virulent RH strain for acute infection survival and the non-virulent Tehran strain for chronic infection, based on reduction of brain tissue cysts. Results: Vaccinated mice exhibited strong antigen-specific immunity, with elevated total IgG, IgG1, and IgG2a titers. Enhanced IFN-γ production and lymphocyte proliferation confirmed cellular activation. These responses correlated with reduced brain cyst counts after infection with the avirulent Tehran strain and prolonged survival with decreased parasite burden following virulent RH strain challenge, indicating improved protection. Conclusion: Co-delivery of IL-12 enhanced both the immunogenicity and protective efficacy of the CDPK3–MIC8–ROP22 multi-epitope DNA vaccine by inducing a Th1-biased response that conferred protection against acute and chronic T. gondii infection. These findings support this vaccination strategy as a promising approach for toxoplasmosis control and highlight the need for further evaluation in diverse animal models and clinical settings to confirm safety, efficacy, and long-term immunity. Copyright © 2026 Abasi et al. Published by Tehran University of Medical Sciences.
Related Docs
View other Related Docs
1. Evaluation of Immunogenicity and Protective Effect of Dna Vaccine Encoding Surface Antigen1 (Sag1) of Toxoplasma Gondii and Tlr-5 Ligand As a Genetic Adjuvant Against Acute Toxoplasmosis in Balb/C Mice, Biologicals (2019)
2. Ascorbic Acid and Α-Tocopherol in the Inactivated Sars-Cov-2 Vaccine Formulation: Induction of the Th1 Pattern in Aged Mice, Viral Immunology (2024)
3. Evaluation of Immune Responses to a Dna Vaccine Encoding Ag85a-Cfp10 Antigen of Mycobacterium Tuberculosis in an Animal Model, Jundishapur Journal of Microbiology (2019)
Experts (# of related papers)
View all Related Experts
Mehdi Shafee Ardestani (3)
Mohammad Hossein Modarressi (2)
Other Related Docs
4. Toxoplasma Gondii Vaccine Candidates: A Concise Review, Irish Journal of Medical Science (2023)
5. In Silico Design and in Vivo Evaluation of Two Multi-Epitope Vaccines Containing Build-In Adjuvant With Chitosan Nanoparticles Against Uropathogenic Escherichia Coli, International Immunopharmacology (2023)
6. Assessment of the Immunogenicity and Protective Efficiency of a Novel Dual-Promoter Dna Vaccine, Harboring Sag1 and Gra7 Genes, From Rh Strain of Toxoplasma Gondii in Balb/C Mice, Infection and Drug Resistance (2019)
7. Formulation of Recombinant H1n1 Hemagglutinin in Mf59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in Balb/C Mice, Viral Immunology (2023)
8. A Non-Pathogenic Leishmania Tarentolae Vector Based- Hcv Polytope Dna Vaccine Elicits Potent and Long Lasting Th1 and Ctl Responses in Balb/C Mice Model, Molecular Immunology (2019)
9. G2 Dendrimer As a Carrier Can Enhance Immune Responses Against Hcv-Ns3 Protein in Balb/C Mice, Avicenna Journal of Medical Biotechnology (2019)
10. Evaluation of Therapeutic Potency of Human Papillomavirus-16 E7 Dna Vaccine Alone and With Interleukin-18 As a Genetic Adjuvant, Scientia Medica (2018)
11. Immunogenicity and Protective Efficacy of Pseudomonas Aeruginosa Type a and B Flagellin Vaccines in a Burned Mouse Model, Molecular Immunology (2016)
12. Induction of Immune Responses by Protein Vaccines Formulated With Adjuvants Against Leishmania Major in Vivo, Comparative Clinical Pathology (2019)
13. A Survey on the Adjuvant Role of Naloxone Alone or Combined With Alum in Vaccination Against Fasciolosis in Balb/C Mice, Acta Parasitologica (2019)
14. A Study on the Immune Response Induced by a Dna Vaccine Encoding Mtb32c-Hbha Antigen of Mycobacterium Tuberculosis, Iranian Journal of Basic Medical Sciences (2017)
15. Enhanced Synergistic Antitumor Effect of a Dna Vaccine With Anticancer Cytokine, Mda-7/Il-24, and Immune Checkpoint Blockade, Virology Journal (2022)
16. Adjuvant Effects of Pseudomonas Aeruginosa Flagellin on the Immunological Patterns of the Hiv-1 Vaccine Candidate: Vaccine Formulations Versus Different Routes of Immunization, Viral Immunology (2022)
17. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
18. Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses, International Immunopharmacology (2021)
19. Evolution of Antigen-Specific Immune Responses in Cutaneous Leishmaniasis Patients, Parasite Immunology (2021)
20. Synergistic Effect of Rsag1 and Rgra2 Antigens Formulated in Plga Microspheres in Eliciting Immune Protection Against Toxoplasama Gondii, Experimental Parasitology (2016)